Navigation Links
Professor Zvi Ram presents phase III recurrent glioblastoma survival and quality of life data from the first pivotal study of the NovoTTF-100A at 15th Annual Society for Neuro-Oncology Scientific Meeting
Date:11/19/2010

the age of 60 who were able to maintain normal daily activities (KPS>80 percent) at the time of enrollment achieved a significant increase in median overall survival time (8.8 vs. 6.6 months, n=110, p< 0.01) and in the 1-year survival rate (35 percent vs. 20 percent, n=110, p< 0.01) when treated with TTF Therapy versus effective chemotherapies. TTF therapy also produced a significant increase in survival time for patients who had failed treatment with bevacizumab (Avastin; Roche) prior to enrollment (4.4 vs. 3.1 months, n=44, p< 0.02). Patients enrolled in the study also reported superior quality of life scores (EORTC QLQ-C30) across a range of lifestyle and symptom categories for TTF therapy compared to the chemotherapy-treated control group.

"The data presented at SNO further validate TTF therapy as a potential treatment option for patients with recurrent glioblastoma tumors," said Asaf Danziger, chief executive officer of Novocure, the trial sponsor. "The suggested improvement in quality of life scores reported by patients receiving TTF therapy is particularly important given the nature of this disease and the strong desire among patients and their caregivers to avoid the side-effects of chemotherapy and radiation."

TTF therapy has been shown in vitro to slow and reverse tumor cell proliferation by inhibiting mitosis, the process by which cells divide and replicate. The NovoTTF-100A device, which weighs about six pounds (three kilograms), creates a low-intensity, alternating electric field within the tumor that exerts physical forces on electrically charged cellular components, preventing the normal mitotic process and causing cancer cell death prior to division.

Novocure is now sponsoring a second phase III study of TTF therapy at 26 centers in the US, Europe, and Israel. This study will enroll 283 patients with newly diagnosed glioblastoma tumors. Patients will be randomized (2 to 1) to receive TTF therapy and temozolomide (Temo
'/>"/>

Contact: Frank Leonard
frank@novo-cure.com
917-656-3518
Edelman Public Relations
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Professor John Shine wins 2010 Prime Ministers Prize for Science
2. CancerCare names Jefferson professor Physician of the Year
3. Professor Cesare Montecucco to receive the 2011 Paul Ehrlich and Ludwig Darmstaedter Prize
4. UT professor defines play, discovers even turtles need recess
5. Virginia Tech professor discovers new TB pathogen
6. Drug to treat alcoholism goal of UH professors research
7. K-State professors book is first to explore Two-Spirit literature in Northwest native groups
8. Louisiana Tech kinesiology professor receives national editorial excellence award
9. WPI computer science professor receives HP Labs Innovation Research Award
10. Linguistics professor examines manufacturers prescription drug websites
11. NJIT professor heads panel studying sudden car acceleration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... Pediatrician-in-Chief Jon McCullers, MD, was recently invited to ... Nature Reviews Microbiology , one of the ... world-renowned infectious disease specialist, and chair of the ... Health Science Center, analyzed the epidemiology and microbiology ... pandemics, as well as more recent 2009 novel ...
(Date:4/17/2014)... Il. (April 17, 2014) Doctors who treat ... called lymphangioleiomyomatosis (LAM) can face an agonizing treatment ... of the disease and help relieve shortness of ... transplants, and sirolimus can cause potentially fatal complications ... pulmonologist Dr. Daniel Dilling, medical director of Loyola ...
(Date:4/17/2014)... April 17, 2014-- Colic affects about one in five ... numerous pediatric visits during the first several months after ... symptoms was showing promise; however, the April 1, 2014 ... Sung, Valerie) reported on a study, "Probiotics and Infant ... L reuteri for infant colic did not ...
(Date:4/17/2014)... April 17, 2014 EcoHealth Alliance, a nonprofit organization ... published a comprehensive review today examining the current state ... The review calls for improved global surveillance strategies to ... recent outbreak of Ebola in West Africa that has ... of Guinea and Liberia. According to the World ...
(Date:4/17/2014)... research team led by Cesar A. Arias, M.D., Ph.D., ... Houston (UTHealth) has identified a new superbug that caused ... appeared in the April 17 issue of The ... superbug is part of a class of highly-resistant bacteria ... which is a major cause of hospital and community-associated ...
Breaking Medicine News(10 mins):Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:New MRSA superbug emerges in Brazil 2
... predictive models of human disease is likely following ... (ESF), which urged for a collaborative effort between ... an enormous amount of data from different sources ... of human tissue, and in vitro laboratory experiments. ...
... WASHINGTON, Nov. 12 The Service Employees,International Union (SEIU), ... the following statement in support of the diagnosis of,and ... by,Senator Max Baucus (D-MT) today:, On the heels ... their top overall issues -- and health care costs ...
... as Rainmakers, SAN DIEGO, Nov. 12 New ... of nurses as hospital revenue,generators, according to a new ... staffing company in,the nation, the survey of 305 hospital ... and the emerging role of nurses as,financial rainmakers., ...
... Pharmaceuticals Inc.,announces the promotion of William N. ... Orthopaedics and Urology Business Unit, recently formed ... formerly Executive Director of,Ferring,s Orthopaedics Business Unit., ... In his new role, Garbarini is responsible ...
... components will feature its productivity maximizing products at ASCB Meeting in San ... ... 2008 -- InVitria InVitria announced today that it will showcase ... Biology Meeting on Dec. 13-17 in San Francisco, CA. InVitria provides animal ...
... record lows,the nation,s stress level hits record highs, but despite ... being more stressed,than ever. In his latest book, Life from ... advice such as, "don,t worry, just,stay calm," not only doesn,t ... problem is explained by new information on the nature of ...
Cached Medicine News:Health News:Computers make sense of experiments on human disease 2Health News:Computers make sense of experiments on human disease 3Health News:SEIU Statement in Support of New Blueprint to Solve Health Care Crisis by Senator Max Baucus 2Health News:AMN Survey: Nurses to Have Bigger Impact on Hospital Revenue 2Health News:Ferring Pharmaceuticals Promotes William Garbarini to Vice President of New Orthopaedics and Urology Business Unit 2Health News:Ferring Pharmaceuticals Promotes William Garbarini to Vice President of New Orthopaedics and Urology Business Unit 3Health News:InVitria to Showcase its Innovative Cell Culture Components at American Society of Cell Biology Annual Meeting 2Health News:InVitria to Showcase its Innovative Cell Culture Components at American Society of Cell Biology Annual Meeting 3Health News:Stress Spikes as Economy Tanks - Psychologist Identifies Why Traditional 'Stress Management' Techniques Don't Work, and Offers Radical New Approach 2
(Date:1/15/2014)... 2014  Manufacturers, suppliers and distributors of innovative medical-related ... their most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the ... the most litigious industry sectors of cases involving ...
(Date:1/15/2014)...  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ("Echo"), ... as a non-invasive, wireless continuous glucose monitoring system, today ... and Interim CEO of Echo Therapeutics, will present at ... Mr. Doman will make a corporate ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... India Drug Forecast and Market Analysis to ... PharmaPoint: Atopic Dermatitis - India Drug ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... 2010 MMRSS, which has been,expanding its geographic footprint over the past 5 years, announced the,opening of ... , , ... Thailand , Indonesia , Sri,Lanka , Bangladesh , Vietnam and UAE, has ... , , ...
... , SUNNYVALE, Calif. , Aug. 3 Accuray Incorporated ... field of radiosurgery, announced today it received Shonin approval from the Japanese ... Robotic Radiosurgery System to treat tumors non-invasively anywhere in the body, inclusive ... as the "CyberKnife® Radiosurgery System." , ...
Cached Medicine Technology:MMRSS now in Hong Kong, Singapore and Taiwan 2Accuray's CyberKnife® G4 System Receives Shonin Approval 2Accuray's CyberKnife® G4 System Receives Shonin Approval 3Accuray's CyberKnife® G4 System Receives Shonin Approval 4
Pilling-Weck, medium clip size, 10mm, rotatable take apart...
Insert only, Ethicon, small clip size...
Ethicon, medium clip size, 10mm, rotatable take apart...
... The Wako CRP-HS assay utilizes turbidimetric ... procedure, measuring over the range of 0.2-28.0 ... can be adapted to most clinical chemistry ... performance in terms of precision, linearity, correlation, ...
Medicine Products: